Healthcare giant Novo Nordisk A/S has made great strides in the research, development, manufacture, and marketing of pharmaceutical products on a global scale. The company operates in two primary segments: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care segment boasts a range of products, including insulins, GLP-1 and related delivery systems, oral anti-diabetic products, obesity medication, glucagon, as well as needles for various chronic diseases. The Rare Disease segment has a strong presence in the biotech industry, developing products for haemophilia, blood disorders, endocrine disorders, growth disorders, and hormone replacement therapies. Novo Nordisk has notable collaboration agreements with Gilead Sciences, Inc. In operation since 1923, the Danish company is headquartered in Bagsvaerd, Denmark.